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Abstract
The conditions that lead to antitumor or protumor functions of natural killer T (NKT) cells against mammalian tumors are 
only partially understood. Therefore, insights into the evolutionary conservation of NKT and their analogs—innate-like T 
(iT) cells—may reveal factors that contribute to tumor eradication. As such, we investigated the amphibian Xenopus laevis iT 
cells and interacting MHC class I-like (XNC or mhc1b.L) genes against ff-2 thymic lymphoid tumors. Upon ff-2 intraperitoneal 
transplantation into syngeneic tadpoles, two iT cell subsets iVα6 and iVα22, characterized by an invariant T-cell receptor 
α chain rearrangement (Vα6-Jα1.43 and Vα22-Jα1.32), respectively, were recruited to the peritoneum, concomitant with a 
decreased level of these transcripts in the spleen and thymus. To address the hypothesize that different iT cell subsets 
have distinct, possibly opposing, roles upon ff-2 tumor challenge, we determined whether ff-2 tumor growth could be 
manipulated by impairing Vα6 iT cells or by deleting their restricting element, the XNC gene, XNC10 (mhc1b10.1.L), on ff-2 
tumors. Accordingly, the in vivo depletion of Vα6 iT cells using XNC10-tetramers enhanced tumor growth, indicating Vα6 iT 
cell-mediated antitumor activities. However, XNC10-deficient transgenic tadpoles that also lack Vα6 iT cells were resistant 
to ff-2 tumors, uncovering a potential new function of XNC10 besides Vα6 iT cell development. Furthermore, the CRISPR/
Cas9-mediated knockout of XNC10 in ff-2 tumors broke the immune tolerance. Together, our findings demonstrate the 
relevance of XNC10/iT cell axis in controlling Xenopus tumor tolerance or rejection.
Introduction
Sharing characteristics of innate and adaptive immune cells, 
natural killer T (NKT) cells have recently emerged as relevant 
immune regulators (1). Akin to innate functions, NKT cells are 
stimulated via interleukin (IL)-12 and IL-18, without cell ex-
pansion, and often independently of T-cell receptor (TCR) en-
gagement (2). Activated NKT cells rapidly produce pro- and 
anti-inflammatory cytokines, facilitated by the accumulation 
of premade transcripts of interferon gamma (IFNγ) and IL-4 (3). 
Based on their TCR, NKT cells are categorized into two groups. 
Type I NKT cells express a TCR composed of Vα14-Jα18 paired to 
one of three different Vβ in mice, and only one rearrangement 
Vα24-Jα18/Vβ11 in humans (4). Due to such limited TCR diver-
sity, type I NKT cells are also known as invariant NKT (iNKT) 
cells. In contrast, type II NKT cells have a broader TCR reper-
toire that is still minimally diversified compared to conven-
tional T cells. Expressed on thymocytes, the non-polymorphic 
major histocompatibility complex (MHC) class  I-like CD1d is 
required for the development of all NKT cells (5). Intriguingly, 
NKT cells recognize lipids and glycolipids in the context of 
CD1d with certain glycolipids interacting with either iNKT or 
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NKT cells are crucial regulators of immune responses against 
pathogens and tumors (7). In tumor immunity, the TCR-based 
subdivision of NKT cells also reflects their opposing func-
tions. Whereas α-galactosylceramide-stimulated iNKT cells 
eradicate tumors, either directly or indirect via CD8 T cells or 
NK cells, type II NKT cells promote tumor growth via the in-
duction of angiogenesis or recruitment of tumor-associated 
macrophages (8). Although mouse iNKT cells are antitumoral 
in diverse cancer models, the stimulation of human iNKT cells 
in clinical trials have resulted in modest effects on cancers (9). 
Comparative studies to define how other vertebrates utilize NKT 
cell analogs—innate-like T (iT) cells in antitumor immune re-
sponses—may give insights into conserved functions of these 
cells. Such knowledge may be valuable in designing better iNKT-
based immunotherapies.
The Xenopus laevis tadpole is a suitable model to investigate 
the evolutionary conservation of iT cell functions. An attractive 
attribute of the tadpole is its suboptimal expression of clas-
sical MHC class  I molecule compensated by the expression of 
Xenopus MHC class I-like XNC genes (10,11). Similar to mamma-
lian MHC class I-like, XNC genes exhibit low polymorphism and 
limited tissue distribution. For example, the XNC gene—XNC10 
(mhc1b10.1.L)—is mainly expressed in the spleen and thymus 
(12,13). Our previous study using Xenopus 15/0 thymic lymphoid 
tumor cells has revealed that XNC10 expressed on tumor cells 
promotes in vivo tumor growth (14). As XNC10 is restricting a 
subset of iT cells, defined by the invariant TCRα Vα6-Jα1.43 re-
arrangement (termed Vα6 iT cells), it is hypothesized to be a 
functional analog of CD1d (15). Functionally, Vα6 iT cells are re-
quired for tadpoles’ resistance to infection by the ranavirus Frog 
Virus 3 as demonstrated by XNC10 reverse genetic loss of func-
tion and XNC10 tetramer-mediated depletion (15–17). Recently, 
we showed that XNC4, restricting Vα45 iT cells, was critical in 
tadpoles’ immunity to Mycobacterium marinum (18).
Cell sorting followed by deep sequencing in X.laevis tad-
pole spleen has revealed that over 80% of the TCRα repertoire 
in the CD8−/CD8low population is represented by six invariant 
T-cell receptor (iTCR) rearrangements: the aforementioned Vα6-
Jα1.43 and Vα45-Jα1.14 iTCR along with four others: Vα22-Jα1.32, 
Vα23-Jα1.3, Vα40-Jα1.22 and Vα41-Jα1.40 (15). This suggests the 
existence of six distinct iT cell subsets (19). In addition to iT 
cell-mediated immunity to pathogens, we determined whether 
iT cell subsets participate in immune responses to Xenopus ff-2 
thymic lymphoid tumor cells, tolerated after transplantation in 
histocompatible inbred F tadpoles (20). Here, we report that two 
distinct iT cell subsets are rapidly recruited to the site of ff-2 
tumor transplantation. Using loss of function reverse genetics 
at the organism and tumor levels and XNC10-tetramers, we in-
vestigated the roles of XNC10 and Vα6 iT in tumor tolerance and 
rejection.
Materials and methods
Tadpoles and ff-2 tumor line
Xenopus laevis tadpoles of F inbred strain were obtained from our Xenopus 
laevis Research Resource for Immunology [XLRRI] (https://www.urmc.
rochester.edu/microbiology-immunology/xenopus-laevis.aspx). Three 
week old tadpoles (developmental stage 54–55) were used in all experi-
ments. Animals were anesthetized in 0.1  g/l tricaine methanesulfonate 
and handled under strict laboratory and UCAR regulations (approval 
number 100577/2003–151). The ff-2 tumor cell line was derived from 
a spontaneous thymic lymphoid tumor in an F inbred adult frog in 
September 1992 (20,21). The cell line has been characterized phenotyp-
ically by flow cytometry (CD5+, CD8+, MHC class  Ilow, MHC class  II−, IgM−) 
and qPCR (expression of Cµ, c-myc, MHC class If, XNC1, 4, 10, 11) as well 
as by its growth capacity following transplantation into MHC compatible 
F tadpoles. Tumor clones wild type (WT) and transfectants are stored in 
aliquots and regularly controlled at the XLRRI; the last control was per-
formed in July 2018.
Generation of XNC10 KD X.laevis embryos and F1 
strain on inbred F background
The XNC10 gene was previously deposited in NCBI GenBank: FJ589642.1. 
Generation of XNC10 KD animals were done via RNAi and I-SceI 
meganuclease as previously described (15,22). Briefly, I-SecI-hU6-shRNA-
XNC10-GFP-I-SceI vector was digested with I-SceI meganuclease for 
40 min at 37°C. Eighty picograms of digest was injected into one-cell em-
bryo. Animals were screened for XNC10 deficiency and raised until sexual 
maturity for intercrossing.
Generation of XNC10 KO ff-2 tumor cells via the 
CRISPR/Cas9 system and homology-directed repair
ff-2 cells (5  × 106) were nucleofected via AmaxaTM-4D-Nucleofection® 
in 100  µl SG solution and CA-137 pulse (Lonza). Two vectors U6-sgRNA-
XNC10-α2-domain-mCherry-Cas9 and XNC10 template with 1000  bp 
homology arms, flanking EF1α-tRFP-puromycin cassette, were used 
equimolarly for a total of 500 ng. Transfected cells were cultured for 24 h 
before adding puromycin. Transfection efficiency was monitored by flow 
cytometry. Single cell-derived colonies were obtained by serial dilution.
Tumor transplantation
Tumor cells (1 × 105) in a volume of 10 µl of amphibian PBS (APBS) were 
intraperitoneally transplanted into F tadpoles. For in vivo XNC10-T injec-
tions, two doses of 1 µg XNC10-T in 10 µl APBS were intraperitoneally ad-
ministered per tadpole, 1 day before and 1 day after tumor challenge. Cells 
were collected by peritoneal lavage.
β2-m-XNC10-tetramer
XNC10-T consisting of the X.laevis β2-m, a glycine-rich linker, the three 
XNC10 α domains, a BirA site, a poly-His, and a V5 epitope was produced 
in Sf9 cells and purified as previously described (15). Eluted fractions were 
tested by Coomassie blue staining and western blotting with anti-V5-HRP 
Ab (ThermoFisher). Protein concentration was determined by the Bradford 
protein assay (Bio-Rad). Protein aliquots were stored at −20°C, thawed and 
used the same day. Biotinylated β2-m-XNC10 proteins were folded into 
tetramers by incubation with fluorochrome-labeled streptavidin at a ratio 
of 5 to 1 over 4 h at RT. The specificity of each batch was tested on adult 
splenocytes by flow cytometry.
Flow cytometry
XRRI provided X.laevis antibodies. Transplanted tumors and PLs were col-
lected by peritoneal lavage, counted with a hemocytometer. Cells were 
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monoclonal antibody (mAb) and a fluorophore-goat-anti-mouse sec-
ondary Ab (BD Biosciences), followed by X.laevis-specific anti-CD8 or anti-
MHC class II biotinylated mAbs and streptavidin-fluorophore (BioLegend). 
To improve the detection of Vα6 iT and CD8 T cells infiltrating tumors in 
the peritoneum, ff-2 tumor cells were stained with the PKH26 Cell Tracer 
(Sigma) before transplantation and gated out. XNC10 KO clones were 
stained with a rabbit anti-XNC10 polyclonal antibody and fluorophore-
goat-anti-rabbit Ab (14). The XNC10-T-fluorophore (5–12.5  µg) was in-
cubated with PLs (15). Dead cells were excluded with propidium iodide 
(BD Pharmingen). Five thousand events per sample, gated on live cells, 
were collected with an Accuri C6 (BD Biosciences). Data were analyzed 
with FlowJo (TreeStar). The gating strategy is depicted in Figure 1A. Briefly, 
tumor and leukocyte populations were gated according to size and granu-
larity (FSC-A/SCC-A) and for single cells (SSC-W/SSC-H), then separated 
into PKH26+ and PKH26− fraction (top panels). As ff-2 tumor cells were 
stained with PKH26 dye before intraperitoneal transplantation, tumor 
cells were within the PKH26+ gate. In contrast, PKH26− gate (non-PKH26) 
included other cells that infiltrated peritoneal cavity following tumor 
transplantation. Absence of XNC10-T cross-reaction with ff-2 tumor cells 
was controlled by gating XNC10-T versus CD8 gated on PKH26 at 3 days 
post-tumor transplantation (middle panels). XNC10-T staining on gated 
PHK26− cells is shown for three consecutive days after tumor transplant-
ation (bottom panels).
Cytospin centrifuge and Giemsa staining
Fifty thousand cells in 150 µl APBS, supplemented with 20% bovine serum 
albumin, were cytocentrifuged (Shandon Southern) at 25–30g, 5 min, at RT, 
air-dried, stained with Giemsa Stain Solution (Gibco) for 3 min, washed in 
APBS for 10 min and mounted in Permount (Fisher Scientific).
In vitro cell proliferation assay
Cells were plated at 500,000 cells per well in triplicates, and their numbers 
were counted at 24, 48 and 72 h using a hemocytometer and Trepan blue 
exclusion staining. Percentage of cell death was <5% per well.
Gene expression analysis
RNA and DNA were extracted with TRIzolTM (Invitrogen). cDNA was 
synthesized using 500  ng DNase-treated RNA, M-MLV RT and oligo(dT) 
(Invitrogen). One microliter of cDNA or 50 ng of DNA was used for qPCR 
and PCR, respectively. PCR reactions were resolved on 1.5% agarose gels 
with EtBr and DNA ladder (Invitrogen). PerfeCTa SYBR® Green FastMix 
ROX (Quantabio) and ABI 7300 real-time PCR were used for qPCR. For qPCR, 
the ∆∆CT method, relative to the endogenous GAPDH and normalized 
against the lowest expression, was used. All primers were validated by 
cloning and sequencing amplified products (Supplementary Table 1, avail-
able at Carcinogenesis Online).
Statistical analysis
Statistical analysis was performed with one-way analysis of variance fol-
lowed by Tukey’s post hoc test or Student’s t-test using online software 
Vassar Stats (http://vassarstats.net/).
Results
Recruitment of Vα6 iT cells to the site of tumor 
transplantation
We previously reported that Vα6 iT cells were detected 
after 15/0 tumor transplantation in the peritoneal cavity of 
histocompatible LG-15 tadpoles (14). Here, we investigated 
whether Vα6 iT cells were also infiltrating the peritoneum after 
ff-2 tumor intraperitoneal (ip) challenge into inbred MHC homo-
zygous F strain tadpoles. Since mammalian NKT cells are early 
responders, we determined Vα6 iT cell recruitment within the 
first 3 days following the tumor challenge. Because ff-2 lymphoid 
tumor cells express surface CD8, we labeled them with the 
tracking fluorescent dye PKH26 before transplantation to distin-
guish tumor cells from infiltrating immune cells (see Materials 
and methods). This allowed us to detect an increase of CD8+ T 
cells at day 3 post-tumor transplantation in a pool of five ff-2 
tumor-bearing tadpoles (Figure 1A). In contrast, infiltration of 
Vα6 iT cells was detected as early as 1 day post-transplantation 
by using XNC10-tetramer (XNC10-T) and by gating out PKH26+ 
cells (Figure 1A and B). Notably, Vα6 iT cells were undetectable 
in the peritoneum of unchallenged tadpoles (16). In addition, 
we measured the relative abundance of Vα6-Jα1.43 iTCR tran-
scripts. As previously shown, Vα6-Jα1.43 iTCR transcripts were 
undetectable in the peritoneal cavity of unchallenged or mock-
challenged tadpoles (Figure 1C) (16). In agreement with the flow 
cytometry data, Vα6-Jα1.43 iTCR transcripts increased signifi-
cantly and gradually after tumor transplantation (Figure 1C). 
Concomitantly, Vα6-Jα1.43 iTCR significantly decreased in the 
spleen and thymus and remained unchanged in the liver (Figure 
1D–F). Thus, the evidence obtained by two different detection 
methods suggests that Vα6 iT cells are recruited to the peri-
toneal cavity from the spleen and thymus following ff-2 tumor 
transplantation.
Kinetics of other iT cells after ff-2 tumor challenge
In mammals, iNKT cells are suppressed by protumor type II 
NKT cells (8). Given that X.laevis possesses six iT cells subsets, 
we were interested to establish whether iT cell subsets other 
than Vα6 iT cells were recruited to the transplanted ff-2 tumor. 
Besides Vα6-Jα1.43 iTCR, we monitored the transcript of the 
other five iTCRα rearrangements upon ff-2 tumor challenge. 
Four of these iTCRα rearrangements (Vα23-Jα1.3, Vα45-Jα1.14, 
Vα40-Jα1.22, Vα41-Jα1.40) were undetectable in the peritoneum 
and their expression remained unchanged in the spleen, thymus 
or liver following tumor transplantation (Supplementary Figure 
S1, available at Carcinogenesis Online). In contrast, the changes in 
Vα22-Jα1.32 iTCR transcript levels mirrored the kinetics of Vα6 
iTCR, albeit at a lower magnitude (Figure 2). Before or following 
a mock tumor challenge, the Vα22-Jα1.32 iTCR transcripts were 
not detected in the peritoneum (Figure 2A). However, the ff-2 
transplantation increased Vα22 iTCR in the peritoneal cavity 
within 1 day post-tumor challenge, in parallel with a decrease of 
these transcripts in the spleen and thymus, but not in the liver 
(Figure 2B–D). To examine the Vα22 iTCR relative abundance, we 
profiled the Vα22 iTCR transcripts in tissues of unchallenged in-
bred F tadpoles. At comparable levels to Vα6 iTCR, Vα22 iTCR 
was expressed in the spleen, thymus and intestine, whereas un-
like Vα6 iTCR, it was undetected in the lung and expressed at 
lower levels in the skin (Supplementary Figure S2, available at 
Carcinogenesis Online). In summary, we identified two different 
iT cell subsets possibly involved in ff-2 tumor immunity.
Outcome of ff-2 tumors transplantation into the 
XNC10 KD F transgenic tadpoles
Vα6 iT cells require XNC10 for their development and transgenic 
(Tg) tadpoles with the XNC10 knockdown (KD) are deficient in 
Vα6 iT cells (15). To study the fate of transplanted ff-2 tumors 
in the XNC10 KD tadpoles, we generated inbred F tadpole line 
with XNC10 KD using RNAi combined with transgenesis (15,22). 
The specificity of XNC10 gene silencing and the decrease of 
Vα6-Jα1.43 iTCR expression was confirmed in the spleens of 
Tg progeny (F1), derived from intercrosses between XNC10 KD 
Tg inbred F parents (F0) (Supplementary Figure S3, available at 
Carcinogenesis Online). XNC10 KD Tg F1 tadpoles and age-matched 
WT controls were then transplanted with ff-2 tumor cells. 
Using flow cytometry and an mAb that specifically recognizes 
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Figure 1. Kinetics of Vα6 iT cells after ff-2 tumor transplantation. Tadpoles at the developmental stage 54–55 were challenged ip with 1 × 105 ff-2 tumor cells. Peritoneal 
cells, spleen, thymus and liver were collected from un-, mock- and tumor-challenged tadpoles to assess kinetics of Vα6 iT cells. Mock challenge was performed by ip 
injection of APBS without tumor cells. (A, B) Tumor cells were additionally stained with PKH26 Cell Tracer (Sigma) before transplantation to discriminate from CD8+ 
T cells. (A) Gating strategy for flow cytometry analysis (top panels), and cytograms showing 3 days following tumor transplantation in PKH26 gate (middle panels) 
and non-PKH26 gate (bottom panels) obtained by pooling five peritoneal lavages from tumor-transplanted tadpoles. (B) Number of XNC10-T+ cells in non-PKH26 gate. 
(C–F) Relative transcript levels of Vα6-Jα1.43 iTCR after ff-2 tumor challenge was quantified in peritoneal cavity (C), spleen (D), thymus (E) and liver (F). Each dot rep-
resents one tadpole. Dotted black line indicates the limit of qPCR detection. Gene expression was normalized against GAPDH transcript expression and represented 
as fold change compared with the lowest level of expression. Results are pooled from three independent experiments and presented as the mean ± SEM (n = 5–17). 
One-way ANOVA, followed by post hoc Tukey’s multiple comparisons tests were used to determine the significance of differences among groups and defined as *P < 0.05, 
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(14,20). We observed a significant decrease in the frequency and 
cell number of ff-2 tumors in the XNC10 KD Tg tadpoles com-
pared with WT controls, 7  days post-transplantation (Figure 
3B). In addition, the forward and scatter profiles of peritoneal 
cells revealed the accumulation of leukocytes with a distinct 
size and complexity in the XNC10 KD Tg hosts (Figure 3A, top 
panel). Intriguingly, the majority of these infiltrating cells were 
MHC class II−. Indeed, although similar in frequency, the num-
bers of MHC class II+ peritoneal leukocytes detected were lower 
in tumor-transplanted XNC10 KD compared with WT recipients 
(Figure 3C). In contrast, a large fraction (90%) of double-negative 
(class II−/CTX−) cells were detected in tumor-transplanted XNC10 
KD (Figure 3A bottom panel).
Because the RNAi-mediated XNC10-deficiency is global and 
established from early embryogenesis, immune mechanisms in-
dependent of Vα6 iT cells may affect ff-2 tumor tolerance. To ad-
dress this possibility, we examined the fate of ff-2 tumor within 
the first 3 days post-tumor challenge. Strikingly, we observed a 
marked decrease in the frequency of ff-2 tumors to non-tumor 
cells at day 3 post-tumor challenge in the XNC10 KD Tg hosts 
(Figure 3D). Concomitantly, the signature transcript levels of 
neutrophils—granulocyte colony-stimulating factor receptor 
(GSCF-R) markedly increased at day 3 in XNC10 KD Tg compared 
with WT hosts (Figure 3E), whereas there was no difference be-
tween transcript levels of macrophage colony-stimulating factor 
receptor between the groups (Supplementary Figure S4, avail-
able at Carcinogenesis Online). These data suggest that the early 
tolerance of ff-2 tumors is compromised in the XNC10-deficient 
tadpoles and that the tumor rejection may involve additional 
immune effector cells depending on the interactions with 
XNC10.
XNC10-T-mediated impairment of Vα6 iT cells at the 
tumor site
Using XNC10 KD Tg tadpoles, we could not exclude the possibility 
that XNC10 is required for the differentiation and function of im-
mune cells other than Va6 iT cells. Besides the identification of 
antigen-specific T cells, polymers of MHC molecules, tetramers, 
can be used to selectively deplete T cells in vivo (23). Thus, we tried to 
deplete or inactivate Va6 T cells using XNC10-tetramers (XNC10-T). 
During the initial characterization, we noted that XNC10-T in-
duced Vα6 iT cell death, especially if not titrated or stained for 
>30 min. To confirm these observations, we incubated freshly iso-
lated splenocytes for 30 and 90 min on ice with 4 different concen-
trations of APC-conjugated XNC10-T (5.0, 7.5, 10.0, 12.5 µg/12.5 µl) 
(Figure 4A) and determined cell death by propidium iodide 
staining. After 30 min, minimal Vα6 iT cell death was detected at 
all range of XNC10-T concentrations (Figure 4A, Supplementary 
Figure S5B, available at Carcinogenesis Online). However, Vα6 iT cell 
death markedly increased when the XNC10-T incubation was pro-
longed to 90 min (Figure 4A, Supplementary Figure S5A, available 
at Carcinogenesis Online). Importantly, XNC10-T only affected the 
viability of Vα6 iT cells because no significant death was meas-
ured in the XNC10-T− cells (Supplementary Figure S5B, available 
at Carcinogenesis Online). Interestingly, conducting this experi-
ment at room temperature increased XNC10-T induced Vα6 iT cell 
death compared with incubation on ice (Supplementary Figure 
S5C, available at Carcinogenesis Online). To obtain in vivo evidence, 
we injected 1 µg of XNC10-T in 10 µl APBS per tadpole ip 1 day 
before and 1  day after ff-2 tumor transplantation. The tadpoles 
were sacrificed 9 and 14 days after ff-2 tumor transplantation to 
allow recovery. We assessed the effects of XNC10-T in vivo treat-




































































































Figure 2. Changes in Vα22-Jα1.32 iTCR transcripts following ff-2 tumor transplantation. Tadpoles at the developmental stage 54–55 were ip challenged with 1 × 105 ff-2 
tumor cells. Peritoneal cells, spleen, thymus and liver were collected from un-, mock- and tumor-challenged tadpoles. Mock challenge was performed by injecting ip 
APBS only. (A–D) Relative transcript level of Vα22-Jα1.32 iTCR was measured in peritoneal cavity (A), spleen (B), thymus (C) and liver (D) following ff-2 tumor challenge. 
Gene expression was normalized against GAPDH expression and represented as fold change compared with the lowest expression level. Dotted black line indicates 
qPCR detection limit. Results are pooled from three independent experiments and presented as the mean ± SEM (n = 6–21). One-way ANOVA followed by post hoc Tukey’s 
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and of cytotoxic factors associated with iT cells (perforin, FasL) and 
by determining tumor growth. The ff-2 tumor-induced increase 
of Vα6-Jα1.43 iTCR in the peritoneum was significantly ablated at 
day 9 after the XNC10-T regimen, whereas there were no differ-
ences between the experimental groups at day 14 (Figure 4B). In 
addition, the decrease of Vα6-Jα1.43 iTCR transcripts in the spleen, 
detected after ff-2 transplantation, was prevented by the XNC10-T 
treatment (Figure 4B). Interestingly, the XNC10-T treatment sig-
nificantly increased Vα22-Jα1.32 iTCR at day 9 in the peritoneum 
(Supplementary Figure S6, available at Carcinogenesis Online). 
The XNC10-T-induced decrease of Vα6-Jα1.43 iTCR transcripts 
was accompanied by a significant reduction of perforin and FasL 
transcript levels in the peritoneal cavity (Figure 4C). Of note, we 
also measured the transcripts of iNOS and Arg1, which reflect the 
polarization state of proinflammatory M1 and anti-inflammatory 
M2 macrophages, respectively. Although the Arg1 expression was 
unchanged among experimental groups, iNOS transcripts signifi-
cantly decreased after the XNC10-T-treated tadpoles (Figure 4D). 
Remarkably, the XNC10-T treatment significantly enhanced ff-2 
tumor growth, as indicated by the increased numbers of tumor 
cells recovered (Figure 4E). In summary, these data suggest that 
Vα6 iT cells are antitumor effectors that can limit ff-2 tumor 
growth.
Generation of XNC10 KO ff-2 tumor clones via the 
CRISPR/Cas9 system
We previously showed that 15/0 lymphoid tumors with stable 
XNC10 KD were acutely rejected by syngeneic LG-15 tadpoles 
Figure 3. Outcome of ff-2 tumor transplantations into XNC10-deficient tadpoles. WT or XNC10 KD Tg F tadpoles at developmental stage 54–55 were ip transplanted 
with 1 × 105 ff-2 tumor cells. At indicated day after transplantation, peritoneal lavages were performed, and cells were subjected to flow cytometry. Frequency and cell 
number of ff-2 tumor cells were assessed with CTX staining. (A–C) Flow cytometry analysis at day 7 following tumor transplantation. (A) Representative FSC-A/SSC-A 
plots showing cells tumor and peritoneal cells (top) and CTX/MHC class II staining (bottom) obtained from WT and XNC10 KD Tg tadpoles. (B) Frequencies and numbers 
of CTX+ ff-2 tumor cells. (C) Frequencies and numbers of CTXneg/MHC class II+ cells. (D) Frequency of retrieved ff-2 tumor cells, stained with CTX, following 3 days after 
transplantation in WT and XNC10 KD Tg tadpoles. (E) Relative abundance of GCSF-R transcripts at days 1, 2 and 3 after transplantation in WT and XNC10 KD Tg tadpoles. 
Gene expression was normalized against GAPDH expression and represented as fold change compared with the lowest level of expression. Results were pooled from 
three independent experiments and presented as the mean ± SEM (n = 10–25). Two-tailed unpaired t test was used to determine significance of differences between 
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(14). To investigate whether XNC10 is also critical for ff-2 tumor-
induced immune suppression, we generated XNC10 knockout 
(KO) ff-2 tumor cells via the CRISPR/Cas9 system and homology-
directed repair (HDR). After co-transfection of ff-2 tumor cells 
with two vectors (sgRNA-XNC10-Cas9-mCherry and XNC10-
homo-tRFP-puro), we selected the clones that incorporated 
the HDR-artificial template with puromycin. The fluorescent 
markers enabled tracking the transfectants by flow cytometry. 
Within 72 h post-transfection, we detected a population of tRFP+ 
cells that expanded from 6.6 to 64.0% over the following 3 weeks 
(Figure 5A). Fluorescent microscopy confirmed that an average 
of 65% ff-2 transfectants were tRFP+ (Figure 5A). Using primers 
Figure 4. XNC10-T impairs Vα6 iT cells and promotes ff-2 tumor growth in vivo. (A) XNC10-T induced Vα6 iT cell death ex vivo. Freshly isolated splenocytes from an 
adult outbred X. laevis were stained with four different concentrations of APC-conjugated XNC10-T (5.0, 7.5, 10.0 and 12.5 µg/12.5 µl) for 30 and 90 min. Live/dead cell 
viability dye—propidium iodide (PI) was used to stain dead cells. (B–F) Two doses of 1 µg XNC10-T in 10 µl APBS were ip administered, 1 day before and 1 day after ip ff-2 
WT tumor challenge. Peritoneal cells and spleens were collected to assess gene expression by qPCR and tumor cell count (cytospin followed by Giemsa staining). (B) 
Transcript levels of Vα6-Jα1.43 iTCR were assessed in peritoneal cavity and spleen following XNC10-T administration in ff-2 tumor-bearing tadpoles. (C, D) Transcript 
levels of perforin and FasL (C) as well as iNOS and Arg1 (D) were detected in peritoneal cavity. (E) ff-2 tumor cells collected by peritoneal lavage and cell numbers were 
assessed by cytospin and Giemsa stain. Each dot represents one tadpole. Dotted black line indicates qPCR detection limit. Gene expression was normalized against 
GAPDH expression and represented as fold change compared with the lowest level of expression. One-way ANOVA followed by post hoc Tukey’s multiple comparisons 
























8 | Carcinogenesis, 2019, Vol. XX, No. XX
flanking the homologous HRD-template and in the tRFP-puro 
cassette, we confirmed the correct integration of the tRFP-puro 
cassette in the XNC10 α2 domain for a subset of transfectants 
(Figure 5B).
Several XNC10 KO ff-2 clones were obtained by serial dilution 
and screened at the genome, transcript and cell surface protein 
levels. The integration of the tRFP-puromycin cassette in the 
XNC10 gene region should prevent amplification of the XNC10 
α2 domain (amplicon of 320 bp), and, thus, indicate the XNC10 
gene disruption (Figure 5C). Among the tested clones, #5 and #6 
were homozygous XNC10 gene KO (XNC10−/−) as genomic pri-
mers did not amplify any product. In addition, the XNC10 tran-
scripts were undetectable in these clones, while the expression 
of several other XNC genes, including XNC1, XNC4 and XNC11, 
was not altered (Figure 5D). The clone #9 was a heterozygous 
XNC10 KO (XNC10−/+) since only about half of the amount of gen-
omic and transcript products were amplified compared with WT 
ff-2. This corresponded to ~50% reduction of XNC10 transcript 
levels consistent with the disruption of one XNC10 allele. The 
clone #3 did not show any evidence of XNC10 gene disruption 
or altered gene expression (XNC10+/+) despite puromycin resist-
ance. This suggests that the tRFP-puro cassette may have been 
accidentally integrated elsewhere in the genome. Of note, clone 
#8 had a mutation in the XNC10 gene that did not involve the 
incorporation of the tRFP-puromycin cassette. Importantly, the 
expression of other highly expressed XNC genes (XNC4, XNC1, 
XNC11) was unaffected in the all screened clones.
In addition, we used an anti-XNC10 pAb that preferentially 
binds to XNC10, although it cross-reacts with other XNC mol-
ecules (14). The binding of anti-XNC10 pAb correlated with the 
transcript levels (Figure 5E). Compared with ff-2 WT, the staining 
intensity of XNC10−/− KO ff-2, clone #5, was decreased (median 
fluorescence intensity: 57 440 versus 10 000). The XNC10+/− KO, 
clone #9, exhibited a smaller decrease in the surface staining 
(Figure 5E). Of note, XNC10+/+ KO ff-2, clone #3, also had a slight 
decrease in anti-XNC10 pAb staining, compared with ff-2 WT. In 
summary, we utilized the CRISPR/Cas9 system and HDR to spe-
cifically knockout the XNC10 gene in ff-2 tumor cells.
In vitro and in vivo growth of XNC10 KO ff-2 
tumor cells
Before transplanting the different XNC10 KO ff-2 clones, we as-
sessed their proliferation in vitro over a period of 72  h (Figure 
6A). Trepan blue exclusion staining was used to assess the per-
centage of dead cells. The proliferation rate of our clones did not 
significantly deviate compared to WT ff-2 (Figure 6A). As such, 
XNC10 KO ff-2 clones did not have any detectable in vitro prolif-
erative defects.
Figure 5. Generation and validation of ff-2 XNC10 KO tumor cells. ff-2 cells were transfected via 4D-Nucleofector™ system (Lonza) with two plasmids: sgRNA-XNC10-
mCherry-Cas9 and homology template of XNC10 α2 with tRFP-puro cassette. Puromycin-containing media facilitated selection. (A) Transfection efficiency monitored 
with flow cytometry. (B) Integration of artificial cassette in XNC10 α2 domain, detected by conventional PCR. (C–E) Single cell clones, generated by serial dilution, were 
screened for the absence of genomic XNC10 PCR product (C), relative expression of XNC10 and other XNC genes (D) and cell surface expression of XNC10, detected by 
polyclonal α-XNC10 Ab (E). Gene expression was normalized against GAPDH and represented as fold change compared with the lowest level of expression. MFI, median 
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We then measured the growth of XNC10 KO ff-2 clones 
7  days after ip transplantation into WT inbred F tadpoles by 
flow cytometry. The transplanted ff-2 WT, XNC10+/+ clone #3 and 
XNC10+/− clone #9 had similar tumor cell frequency (Figure 6B). 
In contrast, the frequency and cell number of the homozygous 
XNC10−/−clone #5 were significantly impaired (Figure 6B and C). 
Interestingly, the number of CTX+ tumor cells was also signifi-
cantly decreased when tadpoles were transplanted with the 
putative heterozygous XNC10+/− clone #9 (Figure 6B and C). In 
conclusion, these data provide further evidence that functional 
XNC10 molecules expressed at a sufficiently high level by ff-2 
tumor are required to overcome rejection in the tadpoles.
Discussion
Due to their immunoregulatory potentials, iNKT cells represent 
a therapeutic prospect against human cancers (24). However, the 
mechanisms that lead to the activation of iNKT cells are only 
partially known. The analysis of evolutionary conservation of 
NKT cell functions may aid in a better understanding of NKT 
cell roles in the context of tumors. The X.laevis tadpole is valu-
able in addressing the evolutionary relevance of NKT cells (25). 
Apart from being the only ectothermic vertebrate with trans-
plantable lymphoid tumor cell lines and compatible MHC inbred 
animals, X.laevis has well-characterized NKT cell analogs—iT 
cells interacting with XNC (15,16,18). Here, we identified two iT 
cell subsets, defined by Vα6 and Vα22 iTCR, probably involved 
in tumor immune responses, and showed that Vα6 iT cells are 
antitumoral. We also provide evidence that the ff-2 tumor-
induced tolerance can be breached at both the organism and 
tumor cell levels by targeting the same gene, XNC10.
Our data indicate a rapid infiltration of iT cells to the 
tumor site consistent with mammalian NKT cell features (7). 
Although we cannot exclude a possible Vα6 iT cell expansion 
Figure 6. XNC10 KO ff-2 tumor cells have no proliferative in vitro defect but are rejected by syngeneic F tadpoles. (A) In vitro proliferation rate of XNC10 KO ff-2 tumor 
cells, assessed by plating 500 000 cells per well of each tumor clone in triplicates. Cell number was evaluated at 24, 48 and 72 h using a hemocytometer and Trepan 
blue exclusion staining; percentage of dead cells never reached 5% per well. Values are presented as the mean ± SEM. Statistical differences were determined using a 
nonparametric Mann–Whitney U test. (B and C) Rejection of XNC10 KO ff-2 tumor clones by syngeneic F tadpoles. F tadpoles at the developmental stage 54/55 were ip 
transplanted with 1 × 105 ff-2 tumor cells: WT, non-mutated XNC10+/+ clone #3, heterozygous XNC10+/− KO clone #9, homozygous XNC10−/− KO clone #5. At day 7 after 
tumor transplantation, peritoneal lavages were performed, cells counted and stained with CTX for flow cytometry. (B) Representative flow plots of peritoneal exudates 
stained with CTX mAb. (C) Frequency and cell number of CTX+ ff-2 tumor cells. Data pooled from two independent experiments and represented with the mean ± SEM 
(n = 3–5). One-way ANOVA followed by post hoc Tukey’s multiple comparisons tests were used to determine the significance of differences among groups and defined as 
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or a preferential retention in the peritoneum, the recruitment 
of these cells appears to be a reasonable explanation. It is con-
sistent with the increase of Vα6 iT cells and their iTCR tran-
scripts in the peritoneum, concomitant with the decrease of 
these transcripts in the spleen and thymus. We propose that 
Va6 iT cells are antitumoral because XNC10-T-mediated Va6 iT 
cell depletion results in an increase in tumor cells. Future in-
vestigations will establish whether Vα6 iT cells exert antitumor 
functions directly or indirectly via other immune cells. Based on 
previous reports, Vα6 iT cells are characterized as CD4−, CD8α/α− 
or dim, which is also reminiscent of mammalian iNKT cells 
(14,15). As mammalian CD8/CD4 double-negative liver-derived 
but not thymic-derived iNKT cells are antitumoral (26), it will 
also be interesting to investigate whether Vα6 iT cells derived 
from different tissues have distinct antitumor potentials.
The Vα22 iT cell subset is still not well understood. 
Interestingly, Vα22 iTCR transcript levels do not change after 
virus or microbial infections (16,18). Therefore, the increase of 
Vα22 iTCR after tumor challenge and in the XNC10-T treatment 
experiment suggests that Va22 iT cells are specialized toward tu-
mors. We also found that the distribution of Vα22 iTCR transcripts 
differs between inbred F and outbred animals that were used in 
the above-mentioned pathogen studies (19). However, this finding 
is not unique to Xenopus as different mouse strains have char-
acteristic iNKT cell tissue allocations (27). Still, the distribution 
of Vα22 iTCR transcripts differs from Vα6 iTCR arguing for the 
relevance of this iT subset in tumor responses. It is probable that 
one of the XNC molecules interacts with Vα22 iT cells. For now, 
we can only speculate about the functions of these two X.laevis 
iT cell subsets in response to ff-2 tumor. The mammalian tumor 
immunity is directed by the simultaneous activities of antitumor 
iNKT and protumor type II NKT cells (28). The balance between 
the activation states of these NKT cell subsets can either promote 
tumor growth or facilitate tumor eradication. It is plausible that 
the Xenopus immune system has evolved a similar or convergent 
mechanism based on two antagonistic iT cell subsets.
In addition to the importance of iT cells in tumor immunity, 
our study shows that tumor tolerance can be controlled by the 
degree of XNC10 expression on ff-2 tumors. Using the CRISPR/
Cas9 system combined with HDR, we generated XNC10 KO 
ff-2 tumors that were rejected by F tadpoles following trans-
plantation. These findings are in agreement with our previous 
report in which XNC10 silencing in 15/0 tumor cells rendered 
those tumors vulnerable to the immune-mediated killing (14). 
Although both 15/0 and ff-2 tumor cell lines are derived from 
thymic lymphoid tumors, they are genetically unrelated. Where 
15/0 originated from a cloned female frog LG-15 with MHC a/c, 
ff-2 tumor arose in an inbred F frog MHC homozygous f/f (21). 
Moreover, unlike 15/0, ff-2 tumors express classical MHC class Ia 
at low level and have a chromosomal translocation (20,29). 
Rejection of two different tumors resulting from the XNC10 de-
ficiency suggests that the XNC10 expression by these tumors 
prevents or overcomes the antitumor immune response. It is 
noteworthy that ff-2 tumor with a heterozygous XNC10 deletion 
was also rejected with a slower kinetics. It is possible that a high 
expression level of XNC10 by tumors overstimulates Va6 iT cells 
and in turn favors a protumor microenvironment.
We have previously proposed that XNC10 and Vα6 iT cells in 
Xenopus are functional analogs of mammalian CD1d and NKT 
cells (15). As NKT cells hold a promise against human cancers, 
the role of CD1d in tumor immunity is under active investiga-
tion. The majority of mouse studies have demonstrated that 
CD1d expression on tumor cells facilitates iNKT cell-mediated 
tumor eradication and that CD1d-deficient tumors are resistant 
to cell-mediated cytotoxicity (9). These reports can be diffi-
cult to reconcile with the data presented here. However, some 
human data are inconsistent with murine models. For example, 
CD1d expression on leukemia and renal cancers is associated 
with worse patient survival (30,31). Furthermore, a recent re-
port using human leukemic cells demonstrated that higher 
CD1d expression correlated with cancer aggressiveness (32). The 
different outcomes of the CD1d expression on tumor growth 
may relate to tumor types, stages or CD1d ligands. Different 
glycolipids binding CD1d elicit opposing protumor or antitumor 
responses (24,33).
Besides CD1d, human CD1b and CD1c expressed on mouse 
tumor cell lines promote antitumor responses (34,35). Akin to 
our results, certain nonclassical MHC class  Ib molecules are 
strongly associated with protumor responses. For example, 
human leukocyte antigen (HLA)-E and HLA-G are indicators of 
tumor escape and used as prognostic markers for worsening dis-
eases (36,37). It is thought that the balance between antitumor 
and protumor activities of different MHC molecules determines 
tumor tolerance or rejection. Apart from the XNC10 gene, 15/0 
and ff-2 tumor cells express other XNC genes, including XNC1, 
XNC4 and XNC11. It is possible that each of these genes influ-
ences tumor fate differently. That notion is supported by our 
earlier study where 15/0 tumors, deficient in all XNC genes, were 
more aggressive upon in vivo transplantation compared with WT 
15/0 tumors (38).
Interestingly, our findings demonstrate that different im-
mune responses can be obtained when XNC10 is impaired at the 
tumor cell or organism levels. In contrast to WT controls, trans-
genic XNC10 KD inbred F tadpoles did not support ff-2 tumor 
growth. Consistent with our results, two reports demonstrated 
that CD1d−/− KO mouse are more resistant to certain types of can-
cers (39,40). However, these studies did not elucidate a possible 
mechanism. Here, we observed that the early rejection of ff-2 
tumor in the transgenic XNC10 KD hosts was correlated with an 
increased transcript level of GCSF-R, a signature of neutrophils. 
It remains to be determined whether silencing of XNC10 affects 
the development and function of other immune cells such as 
neutrophils.
It is also possible that distinct ligands presented in the con-
text of XNC10 result in different physiological outcomes. The 
identity of XNC10 ligand(s) is currently unknown. However, nu-
cleotide sequence comparisons of the putative ligand binding 
regions have revealed that XNC10 lacks residues that enable 
peptide binding, suggesting lipid ligands (12,13). Although CD1d 
performs immune functions via stimulation of iTCR, other MHC 
class  I-like molecules can ligate with non-TCR receptors. For 
example, besides presentation of microbial antigens to TCR, 
H2M3 is recognized by the inhibitory NK receptor Ly49A (re-
viewed in ref. (41)). Similarly, human HLA-E can interact with 
TCR expressed on CD8 T cells in responses against M. tubercu-
losis but predominantly ligates with the members of NKG2-CD94 
NK receptors (42–44). Notably, HLA-E/Qa-1b ligation to different 
members of the NKG2-CD94 family results in either activating 
or inhibitory signals. In the context of tumor immunity, another 
member of the HLA family, HLA-G, is involved in promoting 
tumor immune evasion via binding to inhibitory receptor Ig-like 
transcripts 2 and 4 (ILT2, ILT4) expressed on myelomonocytic 
cells as well as on NK and T cells (37). Although we have shown 
that T cell sorted with XNC10-T express the invariant Vα6-Jα1.14 
iTCR rearrangement (15), this does not exclude a possible inter-
action of XNC10 with non-TCR receptors. The identification of 
non-TCR cell receptors in Xenopus is limited by the high evo-
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genes (45). Still, putative activating and inhibitory NK-like re-
ceptors in Xenopus have been identified (46–48). In addition, 
X.tropicalis and X.laevis genome harbor 75 members of Fc-like 
receptors (49). It would be interesting to see whether XNC10 ex-
pressed on tumor cells can interact with either of these Fc-like 
receptors.
To conclude, our studies provide compelling evidence that 
MHC class I-like molecules and iT cells are critically involved 
in tumor immunity, not only in mammals but also across 
jawed vertebrates as exemplified in X.laevis. Furthermore, 
our experiments provide evidence that the XNC10 gene is 
critical for the immune evasion strategy of Xenopus lymphoid 
tumors.
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